SE0004455D0 - Method of neuronal regeneration in the central nervous system - Google Patents

Method of neuronal regeneration in the central nervous system

Info

Publication number
SE0004455D0
SE0004455D0 SE0004455A SE0004455A SE0004455D0 SE 0004455 D0 SE0004455 D0 SE 0004455D0 SE 0004455 A SE0004455 A SE 0004455A SE 0004455 A SE0004455 A SE 0004455A SE 0004455 D0 SE0004455 D0 SE 0004455D0
Authority
SE
Sweden
Prior art keywords
substance
nervous system
central nervous
neuronal regeneration
ageing
Prior art date
Application number
SE0004455A
Other languages
Swedish (sv)
Inventor
Milos Pekny
Original Assignee
Milos Pekny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milos Pekny filed Critical Milos Pekny
Priority to SE0004455A priority Critical patent/SE0004455D0/en
Publication of SE0004455D0 publication Critical patent/SE0004455D0/en
Priority to AU2002223170A priority patent/AU2002223170A1/en
Priority to PCT/SE2001/002656 priority patent/WO2002043654A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a pharmaceutical composition comprising a substance that upon administration to a patient leads to an inhibition of extension of cellular processes of astrocytes and/or a retraction of said cellular processes. Disclosed is also use of said substance for the production of a pharmaceutical composition for treatment of a condition selected from the group consisting of brain injury, spinal cord injury, stroke, neurodegenerative diseases, neuronal and/or synaptic loss associated with ageing, disorders of the brain associated with ageing and diabetic retinopathy, and also a method for treatment of said conditions wherein said substance is administered to a patient.
SE0004455A 2000-12-01 2000-12-01 Method of neuronal regeneration in the central nervous system SE0004455D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0004455A SE0004455D0 (en) 2000-12-01 2000-12-01 Method of neuronal regeneration in the central nervous system
AU2002223170A AU2002223170A1 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
PCT/SE2001/002656 WO2002043654A2 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004455A SE0004455D0 (en) 2000-12-01 2000-12-01 Method of neuronal regeneration in the central nervous system

Publications (1)

Publication Number Publication Date
SE0004455D0 true SE0004455D0 (en) 2000-12-01

Family

ID=20282072

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004455A SE0004455D0 (en) 2000-12-01 2000-12-01 Method of neuronal regeneration in the central nervous system

Country Status (3)

Country Link
AU (1) AU2002223170A1 (en)
SE (1) SE0004455D0 (en)
WO (1) WO2002043654A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103989682B (en) 2009-04-30 2016-03-30 美国中西部大学 Use the therapy of centhaquin
EP3019242B1 (en) * 2013-07-08 2020-08-19 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
US20150190377A1 (en) * 2014-01-06 2015-07-09 The Regents Of The University Of California, A California Corporation Neuronal regeneration
WO2016172952A1 (en) 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 Application of pi4kiiiα protein and related membrane protein complex in treating alzheimer's disease
CA3171783A1 (en) * 2020-03-31 2021-10-07 Fude HUANG Deuterated oxophenylarsine compound and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
WO1998029547A1 (en) * 1996-12-31 1998-07-09 The Rockefeller University Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof
DE19751949A1 (en) * 1997-11-24 1999-05-27 Bayer Ag Neuronal regeneration and neurodegenerative disease treatment with aminomethyl-chroman derivatives

Also Published As

Publication number Publication date
WO2002043654A2 (en) 2002-06-06
WO2002043654A3 (en) 2002-09-06
AU2002223170A1 (en) 2002-06-11
WO2002043654A8 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
HK1042655A1 (en) Use of erythropoietin in the production of the drugs for the treatment of cerebral ischaemia.
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
ATE537872T1 (en) DEVICE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS USING CHRONIC ADAPTIVE BRAIN STIMULATION DEPENDENT ON LOCAL BIOPOTENTIALS
ATE94069T1 (en) USE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES IN THE MANUFACTURE OF MEDICATIONS FOR BRAIN AND NERVE DISEASES.
KR960700742A (en) ATOPIC DISEASE REMEDY
MX9304110A (en) USE OF COMPLEMENT INHIBITORS FOR THE PREPARATION OF A MEDICATION INTENDED FOR PROPHYLAXIS AND THERAPY OF INFLAMMATORY SKIN AND CUTANEOUS DISEASES AS WELL AS PURPLE.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004084839A3 (en) Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
WO2010018996A3 (en) Human neural stem cell, and pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same
ES2063998T3 (en) USE OF N-ALKYL 1,4-DIHYDROPYRIDIN-DICARBOXYL ACID ESTERS AS MEDICATIONS, NEW COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
SE0004455D0 (en) Method of neuronal regeneration in the central nervous system
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
BR0116653A (en) Medicinal product containing a polyamine as active substance
ES2087407T3 (en) DERIVATIVES OF CHROMAN SUBSTITUTED WITH PIPERIDILMETILO AS AN ACTIVE SUBSTANCE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM.
RU2006147345A (en) METHOD FOR TREATING DISEASES, INJURIES OF THE PERIPHERAL NERVOUS SYSTEM, THEIR CONSEQUENCES AND CONSEQUENCES OF DISTURBANCE OF SPINAL BRAIN CIRCULATION AND SPINAL INJURIES
Caudle et al. Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury
Casale et al. Reduction of spastic hypertonia in patients with spinal cord injury: a double-blind comparison of intravenous orphenadrine citrate and placebo
ATE285773T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
ATE294582T1 (en) USE OF ALPHA-1 ADRENORECEPTOR ANTAGONISTS FOR THE PRODUCTION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF CANCER
WO2003030836A3 (en) Neuronal regeneration
IL194346A0 (en) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
PT1235573E (en) ASSOCIACAO DE RILUZOLE AND GABAPENTINA AND ITS USE AS A DRUG IN THE TREATMENT OF MOTONEURONAL DISEASES
DE60008111D1 (en) USE OF BETA-NAPHTAQUINONE DERIVATIVES FOR PRODUCING A MEDICINAL PRODUCT WITH AN INHIBITING EFFECT ON GLUTAMATE RELEASE BY THE BRAIN